American International Group Inc. increased its stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 7.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,977 shares of the biotechnology company’s stock after buying an additional 727 shares during the period. American International Group Inc.’s holdings in Seres Therapeutics were worth $124,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Fox Run Management L.L.C. acquired a new stake in Seres Therapeutics during the first quarter valued at $136,000. Bank of Montreal Can increased its stake in Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock worth $216,000 after buying an additional 4,829 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in Seres Therapeutics by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after buying an additional 279 shares during the last quarter. American Century Companies Inc. bought a new stake in Seres Therapeutics during the first quarter worth $447,000. Finally, Teachers Advisors LLC increased its stake in Seres Therapeutics by 43.5% in the fourth quarter. Teachers Advisors LLC now owns 41,101 shares of the biotechnology company’s stock worth $407,000 after buying an additional 12,462 shares during the last quarter. Institutional investors and hedge funds own 75.28% of the company’s stock.
Seres Therapeutics, Inc. (NASDAQ:MCRB) opened at 12.94 on Friday. Seres Therapeutics, Inc. has a 52-week low of $8.85 and a 52-week high of $15.09. The company’s market capitalization is $524.23 million. The firm has a 50-day moving average of $12.77 and a 200 day moving average of $10.81.
Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The firm had revenue of $3 million during the quarter, compared to analyst estimates of $3 million. During the same quarter in the prior year, the firm earned ($0.70) earnings per share. The business’s revenue for the quarter was up .0% on a year-over-year basis. Equities analysts predict that Seres Therapeutics, Inc. will post ($2.48) earnings per share for the current fiscal year.
A number of brokerages have weighed in on MCRB. HC Wainwright reiterated a “buy” rating and set a $19.00 price target (up from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Canaccord Genuity set a $20.00 price objective on shares of Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Friday, July 14th. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a research note on Friday, May 19th. Finally, Cantor Fitzgerald set a $16.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 4th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Seres Therapeutics presently has an average rating of “Buy” and a consensus price target of $17.00.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.